Lung carcinoids (lung neuroendocrine tumors): integrated classification, molecular biology, diagnosis, and multidisciplinary management
Endocrine Reviews · 2026-05-13 · 47 (3) · 351-374
DOI: 10.1210/endrev/bnag001 ↗Abstract
Abstract This narrative review aims to provide a comprehensive synthesis of current knowledge and guidelines on lung carcinoids, emphasizing the multidimensional approach required for effective diagnosis and management. The manuscript will: (i) define and classify lung carcinoids in accordance with the latest WHO classification system, and emphasize the importance of molecular markers for precise subtyping; (ii) analyze epidemiological trends, discuss prevalence, incidence, and mortality rates, alongside key risk factors including genetic predispositions (MEN1) and precursor lesions such as diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH); (iii) investigate the etiology and carcinogenesis of lung carcinoids, including insights into the molecular hallmarks and pathways that underlie tumor development and progression; (iv) detail clinical presentations, distinguishing pulmonary symptoms from secretory syndromes (carcinoid syndrome and Cushing syndrome), supported by visual aids to elucidate symptom prevalence and implications; (v) present an integrated diagnostic approach, encompassing state-of-the-art imaging modalities (CT, magnetic resonance imaging [MRI], 68Ga-SSA-positron emission tomography [PET]-CT) and advanced molecular pathology techniques; (vi) outline evidence-based treatment strategies, addressing early-stage interventions, systemic therapies, locoregional therapies, and emerging modalities such as immunotherapy and agnostic approaches; (vii) explore the role of multidisciplinary management, highlighting the critical importance of tumor boards dedicated to lung carcinoids and provide a checklist of key items for comprehensive case discussion and decision-making; and (viii) conclude with future perspectives, identifying gaps in current knowledge and suggest directions for research to enhance diagnosis, treatment, and overall patient quality of life.
EUVIMED